Interne link ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10 april 15, 2019 om 11:00 AM UTC
Interne link ProQR to Present at the H.C. Wainwright Global Life Sciences Conference april 01, 2019 om 11:00 AM UTC
Interne link ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership maart 26, 2019 om 08:01 PM UTC
Interne link ProQR traite le premier patient dans l’essai STELLAR de Phase 1/2 du QR-421a pour le syndrome d’Usher de type 2 maart 11, 2019 om 04:45 PM UTC
Interne link ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2 maart 11, 2019 om 12:00 PM UTC
Interne link ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results februari 27, 2019 om 12:00 PM UTC
Interne link ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day januari 29, 2019 om 01:30 PM UTC
Interne link ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10 januari 07, 2019 om 12:00 PM UTC
Interne link ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2 januari 02, 2019 om 12:00 PM UTC